Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression

References

• Adams CM, Mitra R, Xiao Y, Michener P, Palazzo J, Chao A, Gour J, Cassel J, Salvino JM, Eischen CM, et al. 2023. Targeted MDM2 degradation reveals a new vulnerability for p53-inactivated triple-negative breast cancer. Cancer Discov. 13(5):1210–1229. doi: 10.1158/2159-8290.CD-22-1131.
   PubMed Web of Science ®Google Scholar
• Attardi LD, Reczek EE, Cosmas C, Demicco EG, McCurrach ME, Lowe SW, Jacks T. 2000. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev. 14(6):704–718. doi: 10.1101/gad.14.6.704.
   PubMed Web of Science ®Google Scholar
• Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A. 2018. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ. 25(1):104–113. doi: 10.1038/cdd.2017.169.
   PubMed Web of Science ®Google Scholar
• Bernard A, Boidot R, Végran F. 2022. Alternative splicing in cancer and immune cells. Cancers (Basel). 14(7):1726. doi: 10.3390/cancers14071726.
   PubMed Web of Science ®Google Scholar
• Bieging-Rolett KT, Kaiser AM, Morgens DW, Boutelle AM, Seoane JA, Van Nostrand EL, Zhu C, Houlihan SL, Mello SS, Yee BA, et al. 2020. Zmat3 is a key splicing regulator in the p53 tumor suppression program. Mol Cell. 80(3):452–469.e9. doi: 10.1016/j.molcel.2020.10.022.
   PubMed Web of Science ®Google Scholar
• Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, et al. 2011. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 145(4):571–583. doi: 10.1016/j.cell.2011.03.035.
   PubMed Web of Science ®Google Scholar
• Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377(6549):552–557. doi: 10.1038/377552a0.
   PubMed Web of Science ®Google Scholar
• Caelles C, Helmberg A, Karin M. 1994. p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 370(6486):220–223. doi: 10.1038/370220a0.
   PubMed Web of Science ®Google Scholar
• Chen J. 2016. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med. 6(3):a026104. doi: 10.1101/cshperspect.a026104.
   PubMed Web of Science ®Google Scholar
• Chen M-L, Xu P-Z, Peng X-d, Chen WS, Guzman G, Yang X, Di Cristofano A, Pandolfi PP, Hay N. 2006. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 20(12):1569–1574. doi: 10.1101/gad.1395006.
   PubMed Web of Science ®Google Scholar
• Choe JH, Kawase T, Xu A, Guzman A, Obradovic AZ, Low-Calle AM, Alaghebandan B, Raghavan A, Long K, Hwang PM, et al. 2023. Li–Fraumeni syndrome–associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death. Cancer Discov. 13(5):1250–1273. doi: 10.1158/2159-8290.CD-22-0882.
   PubMed Web of Science ®Google Scholar
• Coronel L, Riege K, Schwab K, Förste S, Häckes D, Semerau L, Bernhart SH, Siebert R, Hoffmann S, Fischer M, et al. 2021. Transcription factor RFX7 governs a tumor suppressor network in response to p53 and stress. Nucleic Acids Res. 49(13):7437–7456. doi: 10.1093/nar/gkab575.
   PubMed Web of Science ®Google Scholar
• Cui D, Xiong X, Shu J, Dai X, Sun Y, Zhao Y. 2020. FBXW7 confers radiation survival by targeting p53 for degradation. Cell Rep. 30(2):497–509.e4. doi: 10.1016/j.celrep.2019.12.032.
   PubMed Web of Science ®Google Scholar
• Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. 1995. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82(4):675–684. doi: 10.1016/0092-8674(95)90039-x.
   PubMed Web of Science ®Google Scholar
• Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. 1998. Pten is essential for embryonic development and tumour suppression. Nat Genet. 19(4):348–355. doi: 10.1038/1235.
   PubMed Web of Science ®Google Scholar
• el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B, et al. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell. 75(4):817–825. doi: 10.1016/0092-8674(93)90500-p.
   PubMed Web of Science ®Google Scholar
• El-Deiry WS. 2016. p21(WAF1) mediates cell cycle inhibition, relevant to cancer suppression and therapy. Cancer Res. 76(18):5189–5191. doi: 10.1158/0008-5472.CAN-16-2055.
   PubMed Web of Science ®Google Scholar
• Engeland K. 2018. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ. 25(1):114–132. doi: 10.1038/cdd.2017.172.
   PubMed Web of Science ®Google Scholar
• Farioli-Vecchioli S, Cinà I, Ceccarelli M, Micheli L, Leonardi L, Ciotti MT, De Bardi M, Di Rocco C, Pallini R, Cavallaro S, et al. 2012. Tis21 knock-out enhances the frequency of medulloblastoma in Patched1 heterozygous mice by inhibiting the Cxcl3-dependent migration of cerebellar neurons. J Neurosci. 32(44):15547–15564. doi: 10.1523/JNEUROSCI.0412-12.2012.
   PubMed Web of Science ®Google Scholar
• Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, Levine AJ. 2007. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 67(7):3043–3053. doi: 10.1158/0008-5472.CAN-06-4149.
   PubMed Web of Science ®Google Scholar
• Fischer BA, Chelbi ST, Guarda G. 2020. Regulatory factor X 7 and its potential link to lymphoid cancers. Trends Cancer. 6(1):6–9. doi: 10.1016/j.trecan.2019.11.001.
   PubMed Web of Science ®Google Scholar
• Fischer M. 2016. p21 governs p53’s repressive side. Cell Cycle. 15(21):2852–2853. doi: 10.1080/15384101.2016.1205393.
   PubMed Web of Science ®Google Scholar
• Fischer M. 2017. Census and evaluation of p53 target genes. Oncogene. 36(28):3943–3956. doi: 10.1038/onc.2016.502.
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Li AG, Wei G, Li H-H, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, et al. 2003. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 3(2):117–130. doi: 10.1016/s1535-6108(03)00021-7.
   PubMed Web of Science ®Google Scholar
• Galindo-Moreno M, Giráldez S, Limón-Mortés MC, Belmonte-Fernández A, Sáez C, Japón MÁ, Tortolero M, Romero F. 2020. p53 and FBXW7: sometimes two guardians are worse than one. Cancers (Basel). 12(4):985. doi: 10.3390/cancers12040985.
   PubMed Web of Science ®Google Scholar
• Galindo-Moreno M, Giráldez S, Limón-Mortés MC, Belmonte-Fernández A, Reed SI, Sáez C, Japón MÁ, Tortolero M, Romero F. 2019. SCF(FBXW7)-mediated degradation of p53 promotes cell recovery after UV-induced DNA damage. Faseb J. 33(10):11420–11430. doi: 10.1096/fj.201900885R.
   PubMed Web of Science ®Google Scholar
• Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. 2015. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell. 59(2):298–308. doi: 10.1016/j.molcel.2015.06.011.
   PubMed Web of Science ®Google Scholar
• Gencel-Augusto J, Su X, Qi Y, Whitley EM, Pant V, Xiong S, Shah V, Lin J, Perez E, Fiorotto ML, et al. 2023. Dimeric p53 mutant elicits unique tumor-suppressive activities through an altered metabolic program. Cancer Discov. 13(5):1230–1249. doi: 10.1158/2159-8290.CD-22-0872.
   PubMed Web of Science ®Google Scholar
• Harms K, Nozell S, Chen X. 2004. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci. 61(7–8):822–842. doi: 10.1007/s00018-003-3304-4.
   PubMed Web of Science ®Google Scholar
• Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75(4):805–816.
   PubMed Web of Science ®Google Scholar
• Hassin O, Oren M. 2023. Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov. 22(2):127–144. doi: 10.1038/s41573-022-00571-8.
   PubMed Web of Science ®Google Scholar
• Ho WC, Fitzgerald MX, Marmorstein R. 2006. Structure of the p53 core domain dimer bound to DNA. J Biol Chem. 281(29):20494–20502. doi: 10.1074/jbc.M603634200.
   PubMed Web of Science ®Google Scholar
• Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. 2010. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA. 107(16):7455–7460. doi: 10.1073/pnas.1001006107.
   PubMed Web of Science ®Google Scholar
• Indeglia A, Leung JC, Miller SA, Leu JI-J, Dougherty JF, Clarke NL, Kirven NA, Shao C, Ke L, Lovell S, et al. 2023. An African-specific variant of TP53 reveals PADI4 as a regulator of p53-mediated tumor suppression. Cancer Discov. 13(7):1696–1719. doi: 10.1158/2159-8290.CD-22-1315.
   PubMed Web of Science ®Google Scholar
• Isbel L, Iskar M, Durdu S, Weiss J, Grand RS, Hietter-Pfeiffer E, Kozicka Z, Michael AK, Burger L, Thomä NH, et al. 2023. Readout of histone methylation by Trim24 locally restricts chromatin opening by p53. Nat Struct Mol Biol. 30(7):948–957. doi: 10.1038/s41594-023-01021-8.
   PubMed Web of Science ®Google Scholar
• Israeli D, Tessler E, Haupt Y, Elkeles A, Wilder S, Amson R, Telerman A, Oren M. 1997. A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. Embo J. 16(14):4384–4392. doi: 10.1093/emboj/16.14.4384.
   PubMed Web of Science ®Google Scholar
• Janic A, Valente LJ, Wakefield MJ, Di Stefano L, Milla L, Wilcox S, Yang H, Tai L, Vandenberg CJ, Kueh AJ, et al. 2018. DNA repair processes are critical mediators of p53-dependent tumor suppression. Nat Med. 24(7):947–953. doi: 10.1038/s41591-018-0043-5.
   PubMed Web of Science ®Google Scholar
• Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, et al. 2003. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 4(4):321–328. doi: 10.1016/s1535-6108(03)00244-7.
   PubMed Web of Science ®Google Scholar
• Jeffrey PD, Gorina S, Pavletich NP. 1995. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science. 267(5203):1498–1502. doi: 10.1126/science.7878469.
   PubMed Web of Science ®Google Scholar
• Jennis M, Kung C-P, Basu S, Budina-Kolomets A, Leu JI-J, Khaku S, Scott JP, Cai KQ, Campbell MR, Porter DK, et al. 2016. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev. 30(8):918–930. doi: 10.1101/gad.275891.115.
   PubMed Web of Science ®Google Scholar
• Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science. 252(5013):1708–1711. doi: 10.1126/science.2047879.
   PubMed Web of Science ®Google Scholar
• Kiryu-Seo S, Hirayama T, Kato R, Kiyama H. 2005. Noxa is a critical mediator of p53-dependent motor neuron death after nerve injury in adult mouse. J Neurosci. 25(6):1442–1447. doi: 10.1523/JNEUROSCI.4041-04.2005.
   PubMed Web of Science ®Google Scholar
• Knudson CM, Tung KS, Tourtellotte WG, Brown GA, Korsmeyer SJ. 1995. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science. 270(5233):96–99. doi: 10.1126/science.270.5233.96.
   PubMed Web of Science ®Google Scholar
• Laptenko O, Prives C. 2006. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 13(6):951–961. doi: 10.1038/sj.cdd.4401916.
   PubMed Web of Science ®Google Scholar
• Laptenko O, Shiff I, Freed-Pastor W, Zupnick A, Mattia M, Freulich E, Shamir I, Kadouri N, Kahan T, Manfredi J, et al. 2015. The p53 C-terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain. Mol Cell. 57(6):1034–1046. doi: 10.1016/j.molcel.2015.02.015.
   PubMed Web of Science ®Google Scholar
• Lee YR, Chen M. 2018. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat Rev Mol Cell Biol. 19(9):547–562. doi: 10.1038/s41580-018-0015-0.
   PubMed Web of Science ®Google Scholar
• Leu JIJ, Dumont P, Hafey M, Murphy ME, George DL. 2004. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol. 6(5):443–450. doi: 10.1038/ncb1123.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Oren M. 2009. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 9(10):749–758. doi: 10.1038/nrc2723.
   PubMed Web of Science ®Google Scholar
• Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. 2006. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 23(4):575–587. doi: 10.1016/j.molcel.2006.06.028.
   PubMed Web of Science ®Google Scholar
• Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W. 2012. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 149(6):1269–1283. doi: 10.1016/j.cell.2012.04.026.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang C, Lin M, Zhu W, Liang Y, Hong X, Zhao Y, Young KH, Hu W, Feng Z, et al. 2014. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget. 5(9):2635–2647. doi: 10.18632/oncotarget.1862.
   PubMedGoogle Scholar
• Liu Y, Gu W. 2022. p53 in ferroptosis regulation: the new weapon for the old guardian. Cell Death Differ. 29(5):895–910. doi: 10.1038/s41418-022-00943-y.
   PubMed Web of Science ®Google Scholar
• Luo Y, Hurwitz J, Massagué J. 1995. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature. 375(6527):159–161. doi: 10.1038/375159a0.
   PubMed Web of Science ®Google Scholar
• Mao J-H, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S, Balmain A. 2004. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature. 432(7018):775–779. doi: 10.1038/nature03155.
   PubMed Web of Science ®Google Scholar
• Martín-Caballero J, Flores JM, García-Palencia P, Serrano M. 2001. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res. 61(16):6234–6238.
   PubMed Web of Science ®Google Scholar
• McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ, Lowe SW. 1997. BAX-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA. 94(6):2345–2349. doi: 10.1073/pnas.94.6.2345.
   PubMed Web of Science ®Google Scholar
• Meek DW, Anderson CW. 2009. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol. 1(6):a000950–a000950. doi: 10.1101/cshperspect.a000950.
   PubMed Web of Science ®Google Scholar
• Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. 2003. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 11(3):577–590. doi: 10.1016/s1097-2765(03)00050-9.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC. 1994. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9(6):1799–1805.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed JC. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80(2):293–299. doi: 10.1016/0092-8674(95)90412-3.
   PubMed Web of Science ®Google Scholar
• Moyer SM, Wasylishen AR, Qi Y, Fowlkes N, Su X, Lozano G. 2020. p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo. Proc Natl Acad Sci USA. 117(38):23663–23673. doi: 10.1073/pnas.2008474117.
   PubMed Web of Science ®Google Scholar
• Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, et al. 1998. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 188(11):2033–2045. doi: 10.1084/jem.188.11.2033.
   PubMed Web of Science ®Google Scholar
• Nakano K, Vousden KH. 2001. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 7(3):683–694. doi: 10.1016/s1097-2765(01)00214-3.
   PubMed Web of Science ®Google Scholar
• Natan E, Baloglu C, Pagel K, Freund SMV, Morgner N, Robinson CV, Fersht AR, Joerger AC. 2011. Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer. J Mol Biol. 409(3):358–368. doi: 10.1016/j.jmb.2011.03.047.
   PubMed Web of Science ®Google Scholar
• Nguyen TA, Menendez D, Resnick MA, Anderson CW. 2014. Mutant TP53 posttranslational modifications: challenges and opportunities. Hum Mutat. 35(6):738–755. doi: 10.1002/humu.22506.
   PubMed Web of Science ®Google Scholar
• Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N. 2000. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 288(5468):1053–1058. doi: 10.1126/science.288.5468.1053.
   PubMed Web of Science ®Google Scholar
• Palacios G, Crawford HC, Vaseva A, Moll UM. 2008. Mitochondrially targeted wild-type p53 induces apoptosis in a solid human tumor xenograft model. Cell Cycle. 7(16):2584–2590. doi: 10.4161/cc.7.16.6070.
   PubMed Web of Science ®Google Scholar
• Pant V, Sun C, Lozano G. 2023. Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program. Cell Death Differ. 30(4):897–905. doi: 10.1038/s41418-023-01123-2.
   PubMed Web of Science ®Google Scholar
• Pfister NT, Prives C. 2017. Transcriptional regulation by wild-type and cancer-related mutant forms of p53. Cold Spring Harb Perspect Med. 7(2):a026054. doi: 10.1101/cshperspect.a026054.
   PubMed Web of Science ®Google Scholar
• Robles AI, Bemmels NA, Foraker AB, Harris CC. 2001. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res. 61(18):6660–6664.
   PubMed Web of Science ®Google Scholar
• Rouault JP, Falette N, Guéhenneux F, Guillot C, Rimokh R, Wang Q, Berthet C, Moyret-Lalle C, Savatier P, Pain B, et al. 1996. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet. 14(4):482–486. doi: 10.1038/ng1296-482.
   PubMed Web of Science ®Google Scholar
• Rubin SM, Sage J, Skotheim JM. 2020. Integrating old and new paradigms of G1/S control. Mol Cell. 80(2):183–192. doi: 10.1016/j.molcel.2020.08.020.
   PubMed Web of Science ®Google Scholar
• Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS. 2002. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol. 4(11):842–849. doi: 10.1038/ncb866.
   PubMed Web of Science ®Google Scholar
• Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR. 2000. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem. 275(10):7337–7342. doi: 10.1074/jbc.275.10.7337.
   PubMed Web of Science ®Google Scholar
• Schuler M, Maurer U, Goldstein JC, Breitenbücher F, Hoffarth S, Waterhouse NJ, Green DR. 2003. p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ. 10(4):451–460. doi: 10.1038/sj.cdd.4401180.
   PubMed Web of Science ®Google Scholar
• Shibue T, Takeda K, Oda E, Tanaka H, Murasawa H, Takaoka A, Morishita Y, Akira S, Taniguchi T, Tanaka N, et al. 2003. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev. 17(18):2233–2238. doi: 10.1101/gad.1103603.
   PubMed Web of Science ®Google Scholar
• Stadler SC, Vincent CT, Fedorov VD, Patsialou A, Cherrington BD, Wakshlag JJ, Mohanan S, Zee BM, Zhang X, Garcia BA, et al. 2013. Dysregulation of PAD4-mediated citrullination of nuclear GSK3β activates TGF-β signaling and induces epithelial-to-mesenchymal transition in breast cancer cells. Proc Natl Acad Sci USA. 110(29):11851–11856. doi: 10.1073/pnas.1308362110.
   PubMed Web of Science ®Google Scholar
• Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW. 2001. Regulation of PTEN transcription by p53. Mol Cell. 8(2):317–325. doi: 10.1016/s1097-2765(01)00323-9.
   PubMed Web of Science ®Google Scholar
• Sullivan KD, Galbraith MD, Andrysik Z, Espinosa JM. 2018. Mechanisms of transcriptional regulation by p53. Cell Death Differ. 25(1):133–143. doi: 10.1038/cdd.2017.174.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, et al. 2003. Functional haplotypes of PADI4, encoding ­citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet. 34(4):395–402. doi: 10.1038/ng1206.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, et al. 2010. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA. 107(16):7461–7466. doi: 10.1073/pnas.1002459107.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Venkatesh D, Kanda H, Nakayama A, Hosokawa H, Lee E, Miki T, Stockwell BR, Yokote K, Tanaka T, et al. 2022. GLS2 is a tumor suppressor and a regulator of ferroptosis in hepatocellular carcinoma. Cancer Res. 82(18):3209–3222. doi: 10.1158/0008-5472.CAN-21-3914.
   PubMed Web of Science ®Google Scholar
• Tanikawa C, Espinosa M, Suzuki A, Masuda K, Yamamoto K, Tsuchiya E, Ueda K, Daigo Y, Nakamura Y, Matsuda K, et al. 2012. Regulation of histone modification and chromatin structure by the p53-PADI4 pathway. Nat Commun. 3(1):676. doi: 10.1038/ncomms1676.
   PubMedGoogle Scholar
• Tanikawa C, Ueda K, Nakagawa H, Yoshida N, Nakamura Y, Matsuda K. 2009. Regulation of protein citrullination through p53/PADI4 network in DNA damage response. Cancer Res. 69(22):8761–8769. doi: 10.1158/0008-5472.CAN-09-2280.
   PubMed Web of Science ®Google Scholar
• Tanikawa C, Zhang Y-Z, Yamamoto R, Tsuda Y, Tanaka M, Funauchi Y, Mori J, Imoto S, Yamaguchi R, Nakamura Y, et al. 2017. The transcriptional landscape of p53 signalling pathway. EBioMedicine. 20:109–119. doi: 10.1016/j.ebiom.2017.05.017.
   PubMed Web of Science ®Google Scholar
• Tripathi V, Kaur E, Kharat SS, Hussain M, Damodaran AP, Kulshrestha S, Sengupta S. 2019. Abrogation of FBW7α-dependent p53 degradation enhances p53’s function as a tumor suppressor. J Biol Chem. 294(36):13224–13232. doi: 10.1074/jbc.AC119.008483.
   PubMed Web of Science ®Google Scholar
• Valente LJ, Gray DHD, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, Janic A, Strasser A. 2013. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 3(5):1339–1345. doi: 10.1016/j.celrep.2013.04.012.
   PubMed Web of Science ®Google Scholar
• Varmeh-Ziaie S, Okan I, Wang Y, Magnusson KP, Warthoe P, Strauss M, Wiman KG. 1997. Wig-1, a new p53-induced gene encoding a zinc finger protein. Oncogene. 15(22):2699–2704. doi: 10.1038/sj.onc.1201454.
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303(5659):844–848. doi: 10.1126/science.1092472.
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lu X. 2002. Live or let die: the cell’s response to p53. Nat Rev Cancer. 2(8):594–604. doi: 10.1038/nrc864.
   PubMed Web of Science ®Google Scholar
• Wahid M, Pratoomthai B, Egbuniwe IU, Evans HR, Babaei-Jadidi R, Amartey JO, Erdelyi V, Yacqub-Usman K, Jackson AM, Morris JC, et al. 2023. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion. Cancer Immunol Immunother. 72(12):4001–4014. doi: 10.1007/s00262-023-03534-z.
   PubMed Web of Science ®Google Scholar
• Walker KK, Levine AJ. 1996. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA. 93(26):15335–15340. doi: 10.1073/pnas.93.26.15335.
   PubMed Web of Science ®Google Scholar
• Weber J, de la Rosa J, Grove CS, Schick M, Rad L, Baranov O, Strong A, Pfaus A, Friedrich MJ, Engleitner T, et al. 2019. PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice. Nat Commun. 10(1):1415. doi: 10.1038/s41467-019-09180-3.
   PubMedGoogle Scholar
• Wu GS, Burns TF, McDonald ER, Meng RD, Kao G, Muschel R, Yen T, el-Deiry WS. 1999. Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene. 18(47):6411–6418. doi: 10.1038/sj.onc.1203025.
   PubMed Web of Science ®Google Scholar
• Yeh CH, Bellon M, Nicot C. 2018. FBXW7: a critical tumor suppressor of human cancers. Mol Cancer. 17(1):115. doi: 10.1186/s12943-018-0857-2.
   PubMed Web of Science ®Google Scholar